Gencove

• Booth: 1908

Gencove's SaaS platform combines low-pass whole genome sequencing with a proprietary computation layer. The result is a unique, hardware-agnostic, high-throughput, cost-effective sequencing and analysis solution. Gencove’s platform enables a full transition to sequencing as your source of genomic information. See how at booth 1908.

Brands: Learn how to leverage Gencove’s low-pass whole genome sequencing and analytics platform for population-scale biological insights at booth 1908.

 Press Releases

• BGI and Gencove Extend Agreement to Offer Low-Pass Whole Genome Sequencing and Analysis Services to Advance Global Health and Sustainability (Oct 05, 2022)

  BGI and Gencove Extend Agreement to Offer Low-Pass Whole Genome Sequencing and Analysis Services to Advance Global Health and Sustainability

  Partnership delivers high-volume, cost-efficient, low-pass whole genome sequencing for human genetics and other applications.

  NEW YORK and CAMBRIDGE, MA. -  Gencove, a pioneer of low-pass whole genome sequencing (LPWGS) analysis, and BGI Americas Corporation, US subsidiary of BGI Genomics Co. Ltd. (300676.SZ), one of the world’s leading multi-omics companies, today announced the extension of the subscription and joint marketing agreements. The partnership combines BGI"s sequencing services from proprietary DNBSEQ™ sequencing technology with Gencove’s analysis platform so that high-capacity, cost-efficient whole genome information can be made more accessible and actionable. Both companies are united by a common goal of providing genomic information for a healthier and more sustainable world.

  “Improving hardware cost, speed, and capacity is one part of the equation”, said Joseph Pickrell, Ph.D., co-founder, and CEO of Gencove. “Sequencing large populations generates massive amounts of data. We knew that for genomics to be universally applicable, we needed to help interpret that data to support scientific discovery.”

  Gencove developed a unique software platform that makes whole genome sequencing fast, affordable, and the data more understandable. Gencove’s technology platform is called low-pass whole genome sequencing (LPWGS). Requiring less DNA per sample and using any sequencing machine, the whole genome is read but fewer times. In a step called imputation, the lower depth reads are compared to a fully characterized reference genome. The data is further analyzed depending on the customer’s needs, but the result is highly accurate with reliable genomic information.

  “Gencove’s platform helps us fulfill our mission of providing the highest quality genomic data at industry-leading pricing”, said Charles Bao, Ph.D., general manager of BGI Americas. “The combination of DNBSEQ™ technology-based sequencing with Gencove’s software brings personalized medicine and bio-sustainability much closer to reality. Since BGI and Gencove launched our combined LPWGS solution more than three years ago, we have seen successful adoption and application by many of our customers across a wide range of human, plant, and animal research.”

  With over 20 years of experience, BGI Genomics is one of the world’s leading providers of genomic sequencing services and proteomic services. The company provides highly affordable, integrated services across a broad range of applications, including:

  • Basic research for human, plant, animal, and microbial species
  • Drug discovery and development
  • Agriculture and biodiversity preservation and sustainability

  The partnership means academic institutions, biotechnology, diagnostic, and pharmaceutical companies all over the world can utilize the scale and efficiency of low-pass whole genome sequencing from two trusted leaders in genomics.

  About Gencove

  With additional threats to human health and the challenge of feeding the world’s growing population, demand for genomic information has skyrocketed. Historically, DNA processing options fell into two categories: low-throughput and costly options such as whole genome sequencing, and high-throughput but limited technologies like genotyping arrays. To help scientists make life-saving discoveries, Gencove combines low-pass whole genome sequencing (reading the DNA at shallow depths) with a proprietary software-as-a-service (SaaS) computation layer. The result is a fast, high-volume, and cost-sensitive sequencing solution. As evidence of the technology’s value, the company has hundreds of customers, and the largest genomics service providers in the world partner with Gencove. For more information visit: www.gencove.com and follow us on www.linkedin.com/company/gencove/mycompany/ and twitter.com/Gencove.

• Gencove and Element Biosciences, Inc. Partner to Offer Low-Pass Whole Genome Sequencing and Analysis with the AVITI™ System The Agreement Expands Options for Customers Seeking Cost-Effective, High-Throughput Whole Genome Sequencing (Oct 05, 2022)

  Gencove and Element Biosciences, Inc. Partner to Offer Low-Pass Whole Genome Sequencing and Analysis with the AVITI™ System

  The Agreement Expands Options for Customers Seeking Cost-Effective, High-Throughput Whole Genome Sequencing

  NEW YORK – Gencove, pioneer of low-pass whole genome sequencing and analysis software, and Element Biosciences Inc., developer of the Element AVITI™ System, a new and disruptive DNA sequencing platform, today announced a joint marketing agreement to further reduce the cost and complexity of obtaining genomic information.

  Whole genome sequencing provides a new foundation to advance healthcare, understand pathogens and feed our growing population. Combining the unrivaled performance and flexibility of the AVITI System with Gencove’s software platform democratizes access to genomic information.

  Gencove’s low-pass sequencing and analysis software reduce costs in two ways. First by miniaturizing the way the DNA samples are processed and second by allowing customers to sequence at lower coverages and then upload the data into the Gencove platform for imputation against species-specific haplotype reference genomes. In this way, higher throughput at a lower cost per sample can be achieved.

  “Gencove and Element share a vision to make cost-effective, high-throughput genome-wide information universally available”, said Joseph Pickrell, Ph.D., co-founder, and CEO of Gencove. “This agreement moves the industry closer to ubiquitous sequencing to help solve our civilization's most pressing biological challenges.”

  Element’s proprietary Avidity Sequencing™ chemistries enable exceptional accuracy and cost efficiency, unmatched by other benchtop systems. AVITI offers both short and long-read capabilities on a single platform bringing ultimate freedom and flexibility to users. Gencove and Element validated that the AVITI System data could be processed by the Gencove software platform and generate high-quality germline and somatic variant calling for human health applications.

  “With the launch of our AVITI™ System and the ability to choose low-pass sequencing and imputation, customers do not have to sacrifice accuracy, throughput and cost”, said Shawn Levy, Ph.D., SVP of Applications and Scientific Affairs, Element Biosciences. “Together Element and Gencove can put more genomic data into the hands of scientists and companies worldwide to accelerate life-saving discovery.”

  Results of the validation study and a real-world case study will be presented at this year’s Advances in Genome Biology and Technology (AGBT) General Meeting on June 6-9, 2022. Additionally, Dr. Pickrell will present in the AGBT Element Biosciences lounge at 8:25 am Thursday, June 9th.

  About Gencove

  With additional opportunities to improve human health and the challenge of feeding the world’s growing population, demand for large-scale genomic information is significantly increasing. To meet the need, Gencove combines low-pass whole genome sequencing with a proprietary software-as-a-service computation layer. The result is a hardware-agnostic, high-volume, and cost-effective sequencing and analysis solution. As evidence of the platform's value, the company has hundreds of customers, and the largest genomics service providers in the world partner with Gencove. For more information visit: www.gencove.com and follow us on LinkedIn and Twitter.

• Gencove Raises $10 Million to Meet the Global Demand for Accessible and Interpretable Whole Genome Sequencing at Scale (Oct 05, 2022)

  Gencove Raises $10 Million to Meet the Global Demand for Accessible and Interpretable Whole Genome Sequencing at Scale

  The company’s low-pass genome sequencing and bioinformatics platform provides a new way to power complete, accurate, and affordable genomic discovery

  NEW YORK — October 26, 2021 /PRNewswire/– Gencove, the leading low-pass genome sequencing platform company, today announced the successful close of a $10 million Series A investment bringing the company’s total financing to $16.2 million. The round was led by Lewis & Clark AgriFood with participation from new and existing investors including Spero Ventures, Techammer, Third Kind Venture Capital, and Version One Ventures. Funding will be used for further product development, commercial growth and to build out key business functions.

  DNA sequencing has become the foundation for biological advancements by enabling the exploration of genetic variants and structural changes in DNA. Historically, technologies for genetic testing fall into two categories: low-throughput and costly options such as whole genome sequencing, and high-throughput but limited technologies like genotyping arrays.

  Gencove solves the too much or too little quandary by combining low-pass whole genome sequencing (reading the DNA fewer times) with a proprietary software-as-a-service (SAAS) computation layer. The result is a unique high-throughput and cost-effective whole genome sequencing solution.

  “We believe the next revolution in genomics will be driven by software,” said Joseph Pickrell, Ph.D., co-founder, and CEO of Gencove. “It’s rewarding to work with investors who recognize the value our platform provides to the agricultural, biotechnology, clinical testing, and pharmaceutical industries.”

  In addition to Gencove’s low-pass whole genome sequencing and SAAS platform, the company has developed large cross-species genomic datasets and reference panels. For its customers, these data equate to greater accuracy, more meaning, and increased research flexibility, today and in the future.

  “Gencove’s platform and datasets can help unlock the genetic underpinnings of our health and wellbeing,” said Larry Page, Ph.D., managing director at Lewis and Clark AgriFood. “We are thrilled to be part of a company whose technology has such broad consumer and industrial applications from agrigenomics, biotechnology, virology to medical diagnoses, disease susceptibility, and response to medical treatment.”

  “The new round of funding will enable us to systematically address the significant demand for industrial-scale genomics we’re seeing in the market,” said Tomaz Berisa, Ph.D., Gencove’s co-founder, and CTO. “We look forward to bringing our novel genomics platform to more customers as quickly as possible to support their important work.”

  About Gencove

  With additional opportunities to improve human health and the challenge of feeding the world’s growing population, the need for genomic information has skyrocketed To meet the demand, Gencove combines low-pass whole genome sequencing (fewer DNA reads) with a proprietary software-as-a-service computation layer. The result is a hardware-agnostic, high-throughput, cost-sensitive sequencing and analysis solution. As evidence of the platform’s value, Gencove has partnered with hundreds of customers and the largest genomics service providers worldwide.  For more information visit: www.gencove.com